How Much Does Vyleesi Cost in Nebraska in 2026?

Brand-Name Vyleesi Pricing at Nebraska Pharmacies

The manufacturer list price for Vyleesi, set by Palatin Technologies and distributed through AMAG Pharmaceuticals, sits at approximately $1,200 per month in 2026. That figure holds across Nebraska retail pharmacies in Omaha, Lincoln, Grand Island, and smaller markets. Each carton contains prefilled single-dose autoinjectors of bremelanotide 1.75 mg, dosed subcutaneously as needed before sexual activity [1].

Cash-pay pricing rarely dips below the list figure without a coupon or discount card. GoodRx and similar aggregators may show modest variation between chains (CVS, Walgreens, Hy-Vee Pharmacy), but the spread is typically less than $50. The FDA-approved prescribing information caps use at 8 doses per calendar month and one injection per 24-hour period [1]. Women who use fewer than 8 doses can stretch a single carton, effectively lowering per-month outlay.

Unlike daily oral medications for other conditions, Vyleesi is taken on demand. A patient who uses the drug 3 or 4 times per month may find the effective monthly spend drops to roughly $450 to $600 depending on carton size and pharmacy pricing, because unused autoinjectors carry forward.

Nebraska Medicaid Does Not Cover Vyleesi

Nebraska Medicaid's preferred drug list excludes Vyleesi as of May 2026. The state program does not provide coverage for bremelanotide under any tier, and no prior-authorization pathway currently exists for HSDD therapies within the Nebraska Medicaid formulary. This mirrors the majority of state Medicaid programs nationwide, which classify HSDD drugs as lifestyle medications excluded from mandatory coverage under the Social Security Act's outpatient drug provisions [2].

The Endocrine Society has noted that HSDD affects an estimated 8 to 10 percent of premenopausal women, and that the condition involves measurable disruptions to melanocortin signaling pathways in the central nervous system [3]. The RECONNECT phase III program (two trials, combined N = 1,247) demonstrated that bremelanotide 1.75 mg significantly increased the number of satisfying sexual events (SSEs) versus placebo (mean increase of +0.7 SSEs per month, P < 0.001) and significantly reduced HSDD-related distress on the Female Sexual Distress Scale (FSDS-R) [4]. Despite this clinical evidence, most payers, including Nebraska Medicaid, have not added the drug.

Patients on Nebraska Medicaid who need HSDD treatment should discuss alternatives with their prescriber. Flibanserin (Addyi), an oral serotonin-receptor agonist approved by the FDA in 2015, also lacks Nebraska Medicaid coverage but may carry a different out-of-pocket cost depending on pharmacy [5].

Compounded Bremelanotide Is Legal in Nebraska via 503A Pharmacies

Nebraska permits 503A compounding pharmacies to prepare patient-specific bremelanotide formulations with a valid prescription. A compounded subcutaneous injection of bremelanotide typically costs about $140 per month, roughly 88 percent less than the branded product.

Section 503A of the Federal Food, Drug, and Cosmetic Act allows licensed pharmacies to compound drugs for individual patients when certain conditions are met: the compound must be prepared by a licensed pharmacist, based on a valid prescription, and not essentially a copy of a commercially available product [6]. In practice, compounding pharmacies offering bremelanotide formulate the peptide at the same 1.75 mg subcutaneous dose, but the delivery system may differ (vial-and-syringe rather than autoinjector).

Nebraska's Board of Pharmacy oversees 503A facilities within the state. Patients can also legally receive compounded bremelanotide shipped from out-of-state 503A pharmacies, provided the pharmacy holds appropriate licensure. Before choosing compounded bremelanotide, patients should confirm that their pharmacy sources its peptide from an FDA-registered facility with third-party purity testing, since compounded drugs do not undergo the same premarket review as FDA-approved products [7].

Dr. Sheryl Kingsberg, a clinical psychologist and HSDD researcher at University Hospitals Cleveland Medical Center, has stated: "Bremelanotide works through a different mechanism than flibanserin. It acts on melanocortin receptors in the brain, and its on-demand dosing gives women flexibility that a daily pill does not."

Insurance Coverage for Vyleesi in Nebraska

Commercial insurance coverage for Vyleesi in Nebraska is inconsistent. Some plans administered by Blue Cross Blue Shield of Nebraska, UnitedHealthcare, and Aetna have covered bremelanotide under specialty pharmacy benefits, but most require prior authorization and documented failure of at least one alternative therapy.

A typical prior-authorization pathway requires the prescriber to document that the patient meets DSM-5 criteria for HSDD, is premenopausal, and has tried behavioral therapy or another pharmacologic option [4]. Even after approval, specialty-tier copays can reach $200 to $400 per fill. The RECONNECT trial data showing statistically significant improvement in desire and reduction in distress (FSDS-R Item 13 change of approximately -0.7 vs. placebo, P < 0.001) is often cited in letters of medical necessity [4].

Patients covered by self-insured employer plans (ERISA plans) face a separate formulary process managed by their plan's pharmacy benefit manager (PBM). Express Scripts and CVS Caremark have each listed Vyleesi on at least one formulary tier, though placement varies by plan sponsor. The American College of Obstetricians and Gynecologists (ACOG) recognizes HSDD as a valid clinical diagnosis and supports access to FDA-approved treatments, which can strengthen appeals [8].

Tricare and Veterans Affairs formularies have not added Vyleesi as of 2026. Federal Employees Health Benefits (FEHB) plans vary by carrier.

The Palatin Technologies Savings Card

Palatin Technologies offers a manufacturer savings card that reduces out-of-pocket cost for commercially insured Nebraska patients. The card can lower copays to as little as $0 to $50 per fill, depending on plan design, with a maximum annual benefit that typically caps around $3,000 to $4,000. Government-insured patients (Medicare, Medicaid, Tricare) are ineligible per federal anti-kickback statute rules [6].

To activate the card, patients register through the manufacturer's website or receive enrollment materials from their prescriber's office. The discount applies at participating Nebraska pharmacies and through mail-order specialty pharmacies. Patients should verify activation before each fill, because savings cards sometimes require annual re-enrollment.

For uninsured patients, Palatin also provides a patient-assistance program with income-based eligibility. Documentation requirements include proof of Nebraska residency, household income verification, and a valid prescription from a licensed provider.

Telehealth Prescribing of Vyleesi in Nebraska

Nebraska law permits telehealth prescribing of Vyleesi. A prescriber licensed in Nebraska can evaluate a patient via synchronous video visit and issue a prescription for bremelanotide without an in-person examination, provided the visit meets the standard of care. The Nebraska Department of Health and Human Services updated telehealth regulations following pandemic-era expansions, and remote prescribing of non-controlled substances remains fully authorized [2].

Bremelanotide is not a controlled substance under DEA scheduling, so it does not trigger the additional requirements that apply to Schedule II through V drugs in Nebraska [9]. This makes telehealth a practical access point, particularly for women in rural parts of the state where the nearest specialist may be hours away.

Several national telehealth platforms now include HSDD evaluation and Vyleesi prescribing in their service lines. Patients should confirm that their telehealth provider can route the prescription to a Nebraska pharmacy (retail or compounding) and that the prescriber holds active Nebraska licensure.

How Vyleesi Works: Mechanism and Clinical Evidence

Bremelanotide is a melanocortin-4 receptor (MC4R) agonist. It binds MC4 receptors in the hypothalamus and limbic system to modulate pathways involved in sexual desire. This mechanism is distinct from flibanserin, which acts on serotonin 5-HT1A and 5-HT2A receptors [10]. The FDA approved bremelanotide in June 2019 specifically for acquired, generalized HSDD in premenopausal women [9].

In the two RECONNECT trials (N = 1,247 combined), women self-administered bremelanotide 1.75 mg subcutaneously at least 45 minutes before anticipated sexual activity over 24 weeks [4]. Key results from the published pooled analysis:

• Satisfying sexual events increased by a mean of 1.0 per month with bremelanotide versus 0.3 with placebo
• FSDS-R desire domain scores improved by -1.0 with bremelanotide versus -0.4 with placebo (P < 0.001)
• The most common adverse event was nausea (40% of bremelanotide patients vs. 1% placebo), which typically diminished after the first few doses
• Transient facial flushing occurred in approximately 20% of patients and injection-site reactions in about 13% [4]

A post-hoc analysis published in the Journal of Women's Health found that treatment effects persisted across age subgroups and were not driven by baseline symptom severity, supporting the drug's efficacy across the eligible premenopausal population [11]. The Endocrine Society's 2019 commentary on melanocortin-based therapies noted that MC4R agonism represents a mechanistically novel approach to female sexual dysfunction [12].

Dr. Anita Clayton, professor of psychiatry at the University of Virginia and a principal investigator on the RECONNECT program, stated: "The on-demand dosing model of bremelanotide allows women to use the medication only when they choose, which aligns with how many patients prefer to manage HSDD."

Comparing Cost Options: A Nebraska Summary

The price gap between branded Vyleesi and compounded bremelanotide in Nebraska is significant. Here is a direct comparison for a patient using the drug 4 times per month:

• Brand Vyleesi (retail cash price): approximately $1,200/month
• Brand Vyleesi with savings card (commercially insured): approximately $0 to $50/month copay, subject to annual cap
• Brand Vyleesi with insurance (no savings card): $200 to $400/month specialty copay (plan-dependent)
• Compounded bremelanotide (503A pharmacy): approximately $140/month
• Nebraska Medicaid: not covered

Patients without commercial insurance face the starkest choice. The FDA's guidance on compounding underscores that compounded products lack the same regulatory oversight as approved drugs, so patients should discuss the tradeoffs with their prescriber [7]. For women who do have commercial coverage, the savings card often makes branded Vyleesi the most affordable option in the short term, though annual benefit caps mean the subsidy may run out for frequent users.

Nebraska women weighing these options should also factor in the cost of the prescriber visit itself. A telehealth HSDD evaluation typically runs $75 to $200 out of pocket if insurance does not cover the visit, while an in-person specialist appointment with a gynecologist or sexual-medicine physician may cost $250 to $400 without coverage.

The nausea rate of 40% reported in RECONNECT is worth noting for cost planning: some patients discontinue within the first month due to side effects, and unused autoinjectors from a filled prescription represent sunk cost [4]. Starting with the fewest doses possible (some pharmacies will dispense partial fills of the branded product) can reduce financial risk during the trial period.